Skip to main content
Top
Published in: Medical Oncology 12/2018

Open Access 01-12-2018 | Original Paper

Evaluation of the impact of treatment with hematopoietic stem cells transplantation (HSCT) on biochemical markers of heart function and novel electrocardiographic markers of repolarization in patients with hematological malignancies

Authors: Małgorzata Poręba, Paweł Gać, Lidia Usnarska-Zubkiewicz, Witold Pilecki, Kazimierz Kuliczkowski, Grzegorz Mazur, Marzena Gonerska, Małgorzata Sobieszczańska, Rafał Poręba

Published in: Medical Oncology | Issue 12/2018

Login to get access

Abstract

High-dose chemotherapy (HDC) followed by stem cell transplantation (HSCT) is a well-established method in patients with hematological malignancies, and for last few years, many efforts have been made to estimate short- and long-term efficacy of this method, as well as early and late complications. The present study concentrates on cardiotoxic effects, mainly early changes using biochemical markers such as N-terminal natriuretic peptide type B (NT-proBNP) and cardiac troponins (cTn). Simultaneously, the analysis of 12-lead ECG was done before and after the procedure in which the novel repolarization markers: Tp–e and Tp–e/QT ratio were measured, together with standard markers: QT, QTc. It was found that NT-pro BNP was significantly increased after HSCT in comparison to results before it, and no significant changes were present in Troponin levels. Simultaneously, Tp–e interval and Tp–e/QT ratio were significantly higher after HSCT. The use of cyclophosphamide, advanced age, and higher level of blood cholesterol concentration were risk factors for the increase in NT-proBNP and treatment with cyclophosphamide as well as fludarabine and higher creatinine levels were risk factors for the increase in Tp–e/QT ratio. In conclusion, in the early term evaluation after HSCT in patients with no previously diagnosed heart disease, the mild changes in markers of heart overload and repolarization were noted. The observations suggest that in all patients undergoing HSCT, even the ones without pre-existing cardiovascular disease, the evaluation, and monitoring of heart function should be considered.
Literature
1.
go back to reference Martin P, Counts G Jr, Appelbaum F, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010;28:1011–6.CrossRef Martin P, Counts G Jr, Appelbaum F, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010;28:1011–6.CrossRef
2.
go back to reference Groenning B, Raymond I, Hildebrandt P, et al. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart. 2004;90:297–303.CrossRef Groenning B, Raymond I, Hildebrandt P, et al. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart. 2004;90:297–303.CrossRef
3.
go back to reference Costello-Boerrigter L, Boerrigter G, Redfield M, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006;47:345–53.CrossRef Costello-Boerrigter L, Boerrigter G, Redfield M, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006;47:345–53.CrossRef
4.
go back to reference Brynildsen J, Petäjä L, Pettilä V, et al. The predictive value of NT-proBNP and hs-TnT for risk of death in cardiac surgical patients. Clin Biochem. 2018;53:65–71.CrossRef Brynildsen J, Petäjä L, Pettilä V, et al. The predictive value of NT-proBNP and hs-TnT for risk of death in cardiac surgical patients. Clin Biochem. 2018;53:65–71.CrossRef
5.
go back to reference Rusnak J, Fastner C, Behnes M, et al. Biomarkers in stable coronary artery disease. Curr Pharm Biotechnol. 2017;18:456–71.CrossRef Rusnak J, Fastner C, Behnes M, et al. Biomarkers in stable coronary artery disease. Curr Pharm Biotechnol. 2017;18:456–71.CrossRef
6.
go back to reference Roziakova L, Bojtarova E, Mistrik M, et al. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation. J Exp Clin Cancer Res. 2012;31:13.CrossRef Roziakova L, Bojtarova E, Mistrik M, et al. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation. J Exp Clin Cancer Res. 2012;31:13.CrossRef
7.
go back to reference Witteles RM. Biomarkers as predictors of cardiac toxicity from targeted cancer therapies. J Card Fail. 2016;22:459–64.CrossRef Witteles RM. Biomarkers as predictors of cardiac toxicity from targeted cancer therapies. J Card Fail. 2016;22:459–64.CrossRef
8.
go back to reference Gupta P, Patel C, Patel H, et al. T(p-e)/QT ratio as an index of arrhythmogenesis. J Electrocardiol. 2008;41:567–74.CrossRef Gupta P, Patel C, Patel H, et al. T(p-e)/QT ratio as an index of arrhythmogenesis. J Electrocardiol. 2008;41:567–74.CrossRef
9.
go back to reference Kors J, Ritsema van Eck H, van Herpen G. The meaning of the Tp-Te interval and its diagnostic value. J Electrocardiol. 2008;41:575–80.CrossRef Kors J, Ritsema van Eck H, van Herpen G. The meaning of the Tp-Te interval and its diagnostic value. J Electrocardiol. 2008;41:575–80.CrossRef
10.
go back to reference Castro Hevia J, Antzelevitch C, Tornés Bárzaga F, et al. Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol. 2006;47:1828–34.CrossRef Castro Hevia J, Antzelevitch C, Tornés Bárzaga F, et al. Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol. 2006;47:1828–34.CrossRef
11.
go back to reference Akboğa M, Gülcihan Balcı K, Yılmaz S, et al. Tp-e interval and Tp-e/QTc ratio as novel surrogate markers for prediction of ventricular arrhythmic events in hypertrophic cardiomyopathy. Anatol J Cardiol. 2017;18:48–53.PubMedPubMedCentral Akboğa M, Gülcihan Balcı K, Yılmaz S, et al. Tp-e interval and Tp-e/QTc ratio as novel surrogate markers for prediction of ventricular arrhythmic events in hypertrophic cardiomyopathy. Anatol J Cardiol. 2017;18:48–53.PubMedPubMedCentral
12.
go back to reference Zhao X, Xie Z, Chu Y, et al. Association between Tp-e/QT ratio and prognosis in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Clin Cardiol. 2012;35:559–64.CrossRef Zhao X, Xie Z, Chu Y, et al. Association between Tp-e/QT ratio and prognosis in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Clin Cardiol. 2012;35:559–64.CrossRef
13.
go back to reference Miller W, Shanley R, Dorostkar P. Cardiac QTc interval characteristics before and after hematopoietic stem cell transplantation: an analysis of 995 consecutive patients at a single center. Bone Marrow Transplant. 2015;50:954–60.CrossRef Miller W, Shanley R, Dorostkar P. Cardiac QTc interval characteristics before and after hematopoietic stem cell transplantation: an analysis of 995 consecutive patients at a single center. Bone Marrow Transplant. 2015;50:954–60.CrossRef
14.
go back to reference Akahori M, Nakamae H, Hino M, et al. Electrocardiogram is very useful for predicting acute heart failure following myeloablative chemotherapy with hematopoietic stem cell transplantation rescue. Bone Marrow Transplant. 2003;31:585–90.CrossRef Akahori M, Nakamae H, Hino M, et al. Electrocardiogram is very useful for predicting acute heart failure following myeloablative chemotherapy with hematopoietic stem cell transplantation rescue. Bone Marrow Transplant. 2003;31:585–90.CrossRef
16.
go back to reference Antzelevitch C. T peak-Tend interval as an index of transmural dispersion of repolarization. Eur J Clin Invest. 2001;31:555–7.CrossRef Antzelevitch C. T peak-Tend interval as an index of transmural dispersion of repolarization. Eur J Clin Invest. 2001;31:555–7.CrossRef
17.
go back to reference Bhatia S. Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. Expert Rev Hematol. 2011;4:437–54.CrossRef Bhatia S. Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. Expert Rev Hematol. 2011;4:437–54.CrossRef
18.
go back to reference Armenian SH, Bhatia S. Cardiovascular disease after hematopoietic cell transplantation - lessons learned. Haematologica. 2008;93:1132–6.CrossRef Armenian SH, Bhatia S. Cardiovascular disease after hematopoietic cell transplantation - lessons learned. Haematologica. 2008;93:1132–6.CrossRef
19.
go back to reference Majhail N, Ness K, Burns L, et al. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study. Biol Blood Marrow Transplant. 2007;13:1153–9.CrossRef Majhail N, Ness K, Burns L, et al. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study. Biol Blood Marrow Transplant. 2007;13:1153–9.CrossRef
20.
go back to reference Baker K, Ness K, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood. 2007;109:1765–72.CrossRef Baker K, Ness K, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood. 2007;109:1765–72.CrossRef
21.
go back to reference Armenian SH, Sun CL, Mills G, et al. Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010;16:1138–44.CrossRef Armenian SH, Sun CL, Mills G, et al. Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010;16:1138–44.CrossRef
22.
go back to reference Tichelli A, Bucher C, Rovo A, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood. 2007;110:3463–71.CrossRef Tichelli A, Bucher C, Rovo A, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood. 2007;110:3463–71.CrossRef
23.
go back to reference Tichelli A, Bhatia S, Socie G. Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br J Haematol. 2008;142:11–26.CrossRef Tichelli A, Bhatia S, Socie G. Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br J Haematol. 2008;142:11–26.CrossRef
24.
go back to reference Zamorano J, Lancellotti P, Rodriguez Muñoz D ESC Scientific Document Group, et al. ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC). Eur Heart J. 2016;37:2768–801.CrossRef Zamorano J, Lancellotti P, Rodriguez Muñoz D ESC Scientific Document Group, et al. ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC). Eur Heart J. 2016;37:2768–801.CrossRef
25.
go back to reference Snowden J, Hill G, Hunt P, et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant. 2000;26:309–13.CrossRef Snowden J, Hill G, Hunt P, et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant. 2000;26:309–13.CrossRef
26.
go back to reference Horacek J, Pudil R, Tichy M, et al. Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia. Exp Oncol. 2007;29:343–7. Horacek J, Pudil R, Tichy M, et al. Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia. Exp Oncol. 2007;29:343–7.
27.
go back to reference Masuko M, Ito M, Kurasaki T, et al. Plasma brain natriuretic peptide during myeloablative stem cell transplantation. Intern Med. 2007;46:551–5.CrossRef Masuko M, Ito M, Kurasaki T, et al. Plasma brain natriuretic peptide during myeloablative stem cell transplantation. Intern Med. 2007;46:551–5.CrossRef
28.
go back to reference Favilli S, Frenos S, Lasagni D, et al. The use of B-type natriuretic peptide in paediatric patients: a review of literature. J Cardiovasc Med. 2009;10:298–302.CrossRef Favilli S, Frenos S, Lasagni D, et al. The use of B-type natriuretic peptide in paediatric patients: a review of literature. J Cardiovasc Med. 2009;10:298–302.CrossRef
29.
go back to reference Sandri M, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem. 2005;51:1405–10.CrossRef Sandri M, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem. 2005;51:1405–10.CrossRef
30.
go back to reference Nelson R. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013;40:195–211.CrossRef Nelson R. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013;40:195–211.CrossRef
31.
go back to reference Premstaller M, Perren M, Koçack K, et al. Dyslipidemia and lipid-lowering treatment in a hematopoietic stem cell transplant cohort: 25 years of follow-up data. J Clin Lipidol. 2018;12:464–80.CrossRef Premstaller M, Perren M, Koçack K, et al. Dyslipidemia and lipid-lowering treatment in a hematopoietic stem cell transplant cohort: 25 years of follow-up data. J Clin Lipidol. 2018;12:464–80.CrossRef
32.
go back to reference Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–97.CrossRef Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–97.CrossRef
33.
go back to reference Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. J Egypt Natl Cancer Inst. 2010;102:14–25.CrossRef Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. J Egypt Natl Cancer Inst. 2010;102:14–25.CrossRef
34.
go back to reference Passweg J, Baldomero H, Gratwohl A, et al. The EBMT activity survey: 1990–2010. Bone Marrow Transplant. 2012;47:906–23.CrossRef Passweg J, Baldomero H, Gratwohl A, et al. The EBMT activity survey: 1990–2010. Bone Marrow Transplant. 2012;47:906–23.CrossRef
35.
go back to reference Roziakova L, Bojtarova E, Mistrik M, et al. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation. J Exp Clin Cancer Res. 2012;31:1–6.CrossRef Roziakova L, Bojtarova E, Mistrik M, et al. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation. J Exp Clin Cancer Res. 2012;31:1–6.CrossRef
36.
go back to reference Mavinkurve-Groothui A, Kapusta L, Nir A, et al. The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature. Pediatr Hematol Oncol. 2008;25:655–64.CrossRef Mavinkurve-Groothui A, Kapusta L, Nir A, et al. The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature. Pediatr Hematol Oncol. 2008;25:655–64.CrossRef
37.
go back to reference Daugaard G, Lassen U, Bie P, et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail. 2005;7:87–93.CrossRef Daugaard G, Lassen U, Bie P, et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail. 2005;7:87–93.CrossRef
38.
go back to reference Majhail N, Rizzo J, Lee S, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Rev Bras Hematol Hemoter. 2012;34:109–33.CrossRef Majhail N, Rizzo J, Lee S, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Rev Bras Hematol Hemoter. 2012;34:109–33.CrossRef
39.
go back to reference Nakamae H, Hino M, Akahori M, et al. Predictive value of QT dispersion for acute heart failure after autologous and allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2004;76:1–7.CrossRef Nakamae H, Hino M, Akahori M, et al. Predictive value of QT dispersion for acute heart failure after autologous and allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2004;76:1–7.CrossRef
40.
go back to reference Antzelevitch C, Sicouri S, Di Diego J, et al. Does Tpeak-Tend provide an index of transmural dispersion of repolarization? Heart Rhythm. 2007;4:1114–6.CrossRef Antzelevitch C, Sicouri S, Di Diego J, et al. Does Tpeak-Tend provide an index of transmural dispersion of repolarization? Heart Rhythm. 2007;4:1114–6.CrossRef
41.
go back to reference Yamaguchi M, Shimizu M, Ino H, et al. T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. Clin Sci. 2003;105:671–6.CrossRef Yamaguchi M, Shimizu M, Ino H, et al. T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. Clin Sci. 2003;105:671–6.CrossRef
42.
go back to reference Topilski I, Rogowski O, Rosso R, et al. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias. J Am Coll Cardiol. 2007;49:320–8.CrossRef Topilski I, Rogowski O, Rosso R, et al. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias. J Am Coll Cardiol. 2007;49:320–8.CrossRef
43.
go back to reference Watanabe N, Kobayashi Y, Tanno K, et al. Transmural dispersion of repolarization and ventricular tachyarrhythmias. J Electrocardiol. 2004;37:191–200.CrossRef Watanabe N, Kobayashi Y, Tanno K, et al. Transmural dispersion of repolarization and ventricular tachyarrhythmias. J Electrocardiol. 2004;37:191–200.CrossRef
44.
go back to reference Mugnai G, Benfari G, Fede A, et al. Tpeak-to-Tend/QT is an independent predictor of early ventricular arrhythmias and arrhythmic death in anterior ST elevation myocardial infarction patients. Eur Heart J Acute Cardiovasc Care. 2016;5:473–80.CrossRef Mugnai G, Benfari G, Fede A, et al. Tpeak-to-Tend/QT is an independent predictor of early ventricular arrhythmias and arrhythmic death in anterior ST elevation myocardial infarction patients. Eur Heart J Acute Cardiovasc Care. 2016;5:473–80.CrossRef
45.
go back to reference Hidalgo J, Krone R, Rich M, et al. Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant. 2004;34:615–9.CrossRef Hidalgo J, Krone R, Rich M, et al. Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant. 2004;34:615–9.CrossRef
46.
go back to reference Tonorezos E, Stillwell E, Calloway J, et al. Arrhythmias in the setting of hematopoietic cell transplants. Bone Marrow Transplant. 2015;50:1212–6.CrossRef Tonorezos E, Stillwell E, Calloway J, et al. Arrhythmias in the setting of hematopoietic cell transplants. Bone Marrow Transplant. 2015;50:1212–6.CrossRef
47.
go back to reference Murdych T, Weisdorf D. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977–1997. Bone Marrow Transplant. 2001;28:283–7.CrossRef Murdych T, Weisdorf D. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977–1997. Bone Marrow Transplant. 2001;28:283–7.CrossRef
Metadata
Title
Evaluation of the impact of treatment with hematopoietic stem cells transplantation (HSCT) on biochemical markers of heart function and novel electrocardiographic markers of repolarization in patients with hematological malignancies
Authors
Małgorzata Poręba
Paweł Gać
Lidia Usnarska-Zubkiewicz
Witold Pilecki
Kazimierz Kuliczkowski
Grzegorz Mazur
Marzena Gonerska
Małgorzata Sobieszczańska
Rafał Poręba
Publication date
01-12-2018
Publisher
Springer US
Published in
Medical Oncology / Issue 12/2018
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-018-1221-5

Other articles of this Issue 12/2018

Medical Oncology 12/2018 Go to the issue